Silvercrest Asset Management Group LLC Protagonist Therapeutics, Inc Transaction History
Silvercrest Asset Management Group LLC
- $13.6 Billion
- Q2 2024
A detailed history of Silvercrest Asset Management Group LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Silvercrest Asset Management Group LLC holds 191,168 shares of PTGX stock, worth $8.76 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
191,168
Previous 382,336
50.0%
Holding current value
$8.76 Million
Previous $13.2 Million
50.0%
% of portfolio
0.05%
Previous 0.05%
Shares
14 transactions
Others Institutions Holding PTGX
# of Institutions
212Shares Held
59.1MCall Options Held
19KPut Options Held
107K-
Farallon Capital Management LLC San Francisco, CA5.84MShares$268 Million0.98% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$264 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.29MShares$242 Million3.06% of portfolio
-
Bvf Inc San Francisco, CA3.32MShares$152 Million3.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.24MShares$149 Million0.0% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.25B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...